Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making headlines due to a rise in popularity as weight loss agents—have been ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)—medications for type 2 diabetes and obesity that have recently been making ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing dozens of health conditions. But the semaglutide-like drugs also appear to ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

Glucagon-like peptide 1 receptor agonists (GLP1RA)-medications for type 2 diabetes and obesity that have recently been making headlines due to a rise ...

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

A team of researchers led by a team at Jiangnan University in China have shown they can "orchestrate the secretion of ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.